ICH guideline S12 on nonclinical biodistribution considerations for gene therapy products - Step 2b - Scientific guideline
Table of contents
The objective of this guideline is to provide harmonised recommendations for the conduct of nonclinical biodistribution (BD) studies in the development of gene therapy (GT) products. This guideline provides recommendations for the overall design of nonclinical BD assessments. Considerations for interpretation and application of the BD data to support a nonclinical development programme and the design of clinical trials are also provided. The recommendations in this guideline endeavour to facilitate the development of GT products while avoiding unnecessary use of animals, in accordance with the 3Rs (reduce/refine/replace) principles.
-
List item
ICH guideline S12 on nonclinical biodistribution considerations for gene therapy products - Step 5 (PDF/807.43 KB) (updated)
Adopted
First published: 20/04/2023
Last updated: 11/09/2023
Legal effective date: 30/09/2023
EMA/CHMP/ICH/318372/2021 -
List item
ICH guideline S12 on nonclinical biodistribution considerations for gene therapy products - Step 2b (PDF/588.28 KB)
Draft: consultation closed
First published: 24/06/2021
Consultation dates: 24/06/2021 to 24/10/2021
EMA/CHMP/ICH/318372/2021 -
List item
Overview of comments received on ICH guideline S12 on nonclinical biodistribution considerations for gene therapy products (EMA/CHMP/ICH/318372/2021) (PDF/506.03 KB)
First published: 11/11/2021
EMA/628681/2021